Hester Biosciences Limited (HESTERBIO.BO)
INR 1693.5
(2.36%)
INR 1693.5
(2.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 188.89 Million INR | -29.06% |
| 2022 | 266.27 Million INR | -32.28% |
| 2021 | 393.2 Million INR | 14.2% |
| 2020 | 344.3 Million INR | 18.03% |
| 2019 | 291.71 Million INR | -29.82% |
| 2018 | 415.67 Million INR | 62.24% |
| 2017 | 256.2 Million INR | 8.81% |
| 2016 | 235.45 Million INR | 22.66% |
| 2015 | 191.96 Million INR | 41.19% |
| 2014 | 135.95 Million INR | 43.82% |
| 2013 | 94.53 Million INR | 2.1% |
| 2012 | 92.59 Million INR | 21.7% |
| 2011 | 76.08 Million INR | 2367944.48% |
| 2010 | 3213.00 INR | -99.99% |
| 2009 | 60.33 Million INR | 27.38% |
| 2008 | 47.36 Million INR | -32.73% |
| 2007 | 70.4 Million INR | 36.68% |
| 2006 | 51.51 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 81.99 Million INR | 29.4% |
| 2024 Q1 | 63.36 Million INR | 28.0% |
| 2023 Q4 | 49.5 Million INR | 24.25% |
| 2023 FY | 188.89 Million INR | -29.06% |
| 2023 Q1 | 58.69 Million INR | 29.53% |
| 2023 Q3 | 39.84 Million INR | -2.5% |
| 2023 Q2 | 40.86 Million INR | -30.38% |
| 2022 Q3 | 111.86 Million INR | 61.14% |
| 2022 Q4 | 45.31 Million INR | -59.49% |
| 2022 FY | 266.27 Million INR | -32.28% |
| 2022 Q1 | 39.68 Million INR | -48.62% |
| 2022 Q2 | 69.42 Million INR | 74.95% |
| 2021 Q4 | 77.23 Million INR | -8.97% |
| 2021 FY | 393.2 Million INR | 14.2% |
| 2021 Q2 | 106.23 Million INR | -14.95% |
| 2021 Q3 | 84.84 Million INR | -20.14% |
| 2021 Q1 | 124.9 Million INR | 28.92% |
| 2020 Q4 | 96.88 Million INR | -21.52% |
| 2020 FY | 344.3 Million INR | 18.03% |
| 2020 Q3 | 123.45 Million INR | 84.75% |
| 2020 Q2 | 66.82 Million INR | 16.92% |
| 2020 Q1 | 57.15 Million INR | 108.52% |
| 2019 Q3 | 115.19 Million INR | 76.56% |
| 2019 Q4 | 27.4 Million INR | -76.21% |
| 2019 FY | 291.71 Million INR | -29.82% |
| 2019 Q1 | 83.87 Million INR | -36.29% |
| 2019 Q2 | 65.24 Million INR | -22.21% |
| 2018 Q3 | 128.01 Million INR | 83.55% |
| 2018 Q2 | 69.74 Million INR | -19.18% |
| 2018 Q1 | 86.29 Million INR | 0.0% |
| 2018 FY | 415.67 Million INR | 62.24% |
| 2018 Q4 | 131.64 Million INR | 2.84% |
| 2017 FY | 256.2 Million INR | 8.81% |
| 2016 FY | 235.45 Million INR | 22.66% |
| 2015 FY | 191.96 Million INR | 41.19% |
| 2014 FY | 135.95 Million INR | 43.82% |
| 2013 FY | 94.53 Million INR | 2.1% |
| 2012 Q4 | 20.43 Million INR | -26.1% |
| 2012 FY | 92.59 Million INR | 21.7% |
| 2012 Q1 | 21.01 Million INR | 0.0% |
| 2012 Q2 | 23.48 Million INR | 11.76% |
| 2012 Q3 | 27.65 Million INR | 17.76% |
| 2011 FY | 76.08 Million INR | 2367944.48% |
| 2010 FY | 3213.00 INR | -99.99% |
| 2009 FY | 60.33 Million INR | 27.38% |
| 2008 FY | 47.36 Million INR | -32.73% |
| 2007 FY | 70.4 Million INR | 36.68% |
| 2006 FY | 51.51 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 96.933% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 99.405% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 95.989% |
| Granules India Limited | 4.05 Billion INR | 95.34% |
| Indoco Remedies Limited | 984.6 Million INR | 80.816% |
| Achyut Healthcare Limited | 5.73 Million INR | -3195.359% |
| Ajanta Pharma Limited | 8.16 Billion INR | 97.686% |
| Alkem Laboratories Limited | 17.95 Billion INR | 98.948% |
| Alpa Laboratories Limited | 167.76 Million INR | -12.592% |
| Brooks Laboratories Limited | -195.91 Million INR | 196.412% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 88.305% |
| Bajaj HealthCare Limited | -837.93 Million INR | 122.542% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 74.966% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.661% |
| Eris Lifesciences Limited | 3.91 Billion INR | 95.181% |
| FDC Limited | 3.05 Billion INR | 93.811% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 101.258% |
| Gufic Biosciences Limited | 861.35 Million INR | 78.071% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 95.513% |
| Ipca Laboratories Limited | 5.47 Billion INR | 96.549% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 15.911% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 195.745% |
| Lasa Supergenerics Limited | -217.3 Million INR | 186.924% |
| Laurus Labs Limited | 1.6 Billion INR | 88.235% |
| Lupin Limited | 19.14 Billion INR | 99.013% |
| Mankind Pharma Limited | 19.12 Billion INR | 99.013% |
| Medicamen Biotech Limited | 109.31 Million INR | -72.802% |
| Medico Remedies Limited | 82.9 Million INR | -127.828% |
| Megasoft Limited | -127.46 Million INR | 248.189% |
| NATCO Pharma Limited | 13.88 Billion INR | 98.639% |
| Piramal Pharma Limited | 178.2 Million INR | -5.999% |
| RPG Life Sciences Limited | 876.6 Million INR | 78.452% |
| Sigachi Industries Limited | 571.8 Million INR | 66.966% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.803% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 93.71% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 25.382% |
| Unichem Laboratories Limited | -704.74 Million INR | 126.803% |
| Wanbury Limited | 559.56 Million INR | 66.243% |
| Windlas Biotech Limited | 581.87 Million INR | 67.537% |
| ZIM Laboratories Limited | 172.46 Million INR | -9.524% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 99.511% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 104.878% |
| Divi's Laboratories Limited | 16 Billion INR | 98.819% |
| Procter & Gamble Health Limited | 2 Billion INR | 90.602% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 57.999% |
| Bal Pharma Limited | 73.92 Million INR | -155.526% |
| Strides Pharma Science Limited | -706.14 Million INR | 126.75% |
| Venus Remedies Limited | 284.9 Million INR | 33.701% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 91.291% |
| Nectar Lifesciences Limited | 49.95 Million INR | -278.158% |
| Shilpa Medicare Limited | 318.74 Million INR | 40.739% |
| Aarti Drugs Limited | 1.71 Billion INR | 88.981% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 85.949% |
| Suven Life Sciences Limited | -1.05 Billion INR | 117.976% |
| Ind-Swift Limited | 142.31 Million INR | -32.729% |
| Valiant Laboratories Limited | 3.19 Million INR | -5810.2% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 96.582% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 103.329% |
| Themis Medicare Limited | 435.23 Million INR | 56.601% |
| Hikal Limited | 696.02 Million INR | 72.861% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 98.86% |
| Sequent Scientific Limited | -358.69 Million INR | 152.661% |
| Novartis India Limited | 851.9 Million INR | 77.827% |
| Wockhardt Limited | -4.63 Billion INR | 104.08% |
| Jubilant Pharmova Limited | 771 Million INR | 75.501% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -2563.424% |
| Neuland Laboratories Limited | 3 Billion INR | 93.705% |
| Morepen Laboratories Limited | 961.59 Million INR | 80.357% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -29.364% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 308.219% |